Implantation techniques (predilatation, sizing, and postdilatation) and the incidence of scaffold thrombosis and revascularisation in lesions treated with an everolimuseluting bioresorbable vascular scaffold: Insights from the AIDA trial
Aims: Specific implantation strategies have been proposed for the Absorb bioresorbable vascular scaffold (Absorb BVS) to optimise outcomes. We aimed to analyse whether the occurrence of definite scaffold thrombosis (ScT) and target lesion revascularisation (TLR) in Absorb-treated AIDA patients was influenced by scaffold implantation techniques. Methods and results: Absorb BVS implantation in 1,074 lesions was graded according to definitions of optimal implantation based on predilatation, sizing, and post-dilatation (PSP). Lesion-oriented outcomes (definite ScT and TLR) that occurred during a median follow-up of 707 days were related to the presence or absence of PSP. Of 1,074 lesions, 158 (14.7%) lesions met PSP criteria. The most prevalent reason for not meeting PSP criteria was inadequate sizing: 863 (94.2%). Definite ScT occurred in four of 158 PSP-treated lesions compared with 27 of 916 non PSP-treated lesions, with two-year KM estimates of 3.0% vs. 4.1% and an HR of 1.14 (p=0.811). TLR occurred in eight of 158 PSP-treated lesions compared with 61 of 916 non PSP-treated lesions, with KM estimates of 5.6% vs. 7.1% and an HR of 1.29 (p=0.492). Conclusions: In AIDA, lesions that underwent scaffold implantation according to an optimised Absorb BVS implantation technique did not have lower rates of ScT and TLR compared to scaffold-treated lesions that did not meet PSP criteria.
|Persistent URL||dx.doi.org/10.4244/EIJ-D-17-01152, hdl.handle.net/1765/109729|
Tijssen, R.Y.G. (Ruben Y.G.), van der Kraak, P.H, Elias, J. (Joelle), Van Dongen, I.M. (Ivo M.), Kalkman, D.N. (Deborah N.), Nassif, M. (Martina), … Wykrzykowska, J.J. (2018). Implantation techniques (predilatation, sizing, and postdilatation) and the incidence of scaffold thrombosis and revascularisation in lesions treated with an everolimuseluting bioresorbable vascular scaffold: Insights from the AIDA trial. EuroIntervention, 14(4), e434–e442. doi:10.4244/EIJ-D-17-01152